

5081 '00 JUL 12 P1 54  
JUL 11 2000

The Cosmetic, Toiletry, and Fragrance Association  
Attn: Mr. Thomas J. Donegan, Jr.  
Vice President-Legal & General Counsel  
1101 17<sup>th</sup> St., N.W.,  
Suit 300,  
Washington, District of Columbia 20036-4702

The Soap and Detergent Association  
Attn: Dr. Jenan Al-Atrash,  
Director, Human Health & Safety  
475 Park Avenue,  
New York, New York 10016

Re. Docket Number 75N-183H

Dear Mr. Donegan and Dr. Al-Atrash:

This will acknowledge receipt of your letter of June 30, 2000, regarding the Final Monograph for Health Care Antiseptic Drug Products. We are forwarding your comments to the Dockets Management Branch for inclusion into the subject docket.

We understand your interest in test methodology and agree that test methodology is an important aspect of the final rulemaking.

Please note that in the future, we will forward all correspondence regarding the specific rulemaking to the Dockets Management Branch to be incorporated into the public record.

Sincerely yours,

Charles Ganley, M.D.,  
Director,  
Division of Over-the-Counter Drug Products Drug Products  
Office of Drug Evaluation V  
Center for Drug Evaluation and Research



Cc: HFD-560 Div Files (Healthcare Products)  
HFD-560 Ganley, Katz, Cook, Rachanow, Lumpkins, Rothschild  
HFA-305 Butler (with copy of incoming FAX for filing in docket)

75N-183H

ACK 2